Startups
Genethon develops innovative therapies for rare diseases of the eye, the liver, the immune system and for neuromuscular diseases.
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 26, 2025 | Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025 | Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025 Fri, Sep 26, 2025 18:50 CET Report this content Lund, Sweden, 26 September, 2025. Hansa Biopharm... |
| Dec 3, 2024 | Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome | Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome Tue, Dec 03, 2024 07:00 CET Report this content The trial will be conducted in patients with ... |
| Nov 27, 2023 | Genethon Using AI to Improve Effectiveness of Gene Therapies and Patient Access | CEO Frederic Revah discusses how Artificial Intelligence is creating next-generation gene therapy vectors and reducing bioproduction costs in the latest issue of Genethon’s Newsletter Genethon, a unique non-profit gene therapy R&D organ... |
| Apr 27, 2023 | Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies | Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies Thu, Apr 27, 2023 17:30 CET Report this content Lund, Sweden and Evry, F... |
| Sep 12, 2022 | How WhiteLab Genomics is using AI to aid gene and cell therapy development | French biotech company WhiteLab Genomics has raised $10 million in funding for an AI platform designed to aid the discovery and development of genomic therapies. Founded out of Paris in 2019, recent Y Combinator (YC) graduate WhiteLab Genom... |
Reviews 0
FAQ about Généthon
What has the press written about Généthon?
Parsers VC has collected 6 articles mentioning Généthon, among them “Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025” (Sep 26, 2025) and “Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome” (Dec 3, 2024).
Is Généthon still active?
Yes, Généthon is active; its latest activity on Parsers VC dates from Oct 10, 2025.